ZOLEDRONIC ACID injection solution concentrate

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

Zoledronic Acid (UNII: 6XC1PAD3KF) (Zoledronic Acid Anhydrous - UNII:70HZ18PH24)

제공처:

Sagent Pharmaceuticals

INN (International Name):

Zoledronic Acid

구성:

Zoledronic Acid Anhydrous 0.8 mg in 1 mL

처방전 유형:

PRESCRIPTION DRUG

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

ZOLEDRONIC ACID- ZOLEDRONIC ACID INJECTION, SOLUTION, CONCENTRATE
SAGENT PHARMACEUTICALS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ZOLEDRONIC ACID INJECTION SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZOLEDRONIC ACID
INJECTION.
ZOLEDRONIC ACID INJECTION, CONCENTRATE FOR INTRAVENOUS INFUSION
INITIAL U.S. APPROVAL: 2001
RECENT MAJOR CHANGES
Warnings and Precautions, Osteonecrosis of the Jaw (5.4)
06/2015
INDICATIONS AND USAGE
Zoledronic Acid Injection is a bisphosphonate indicated for the
treatment of:
Hypercalcemia of malignancy. (1.1)
Patients with multiple myeloma and patients with documented bone
metastases from solid tumors, in conjunction with
standard antineoplastic therapy. Prostate cancer should have
progressed after treatment with at least one hormonal
therapy. (1.2)
Important limitation of use: The safety and efficacy of Zoledronic
Acid Injection has not been established for use in
hyperparathyroidism or nontumor-related hypercalcemia. (1.3)
DOSAGE AND ADMINISTRATION
Hypercalcemia of malignancy (2.1)
4 mg as a single-use intravenous infusion over no less than 15
minutes.
4 mg as retreatment after a minimum of 7 days.
Multiple myeloma and bone metastasis from solid tumors. (2.2)
4 mg as a single-use intravenous infusion over no less than 15 minutes
every 3 to 4 weeks for patients with creatinine
clearance of greater than 60 mL/min.
Reduce the dose for patients with renal impairment.
Coadminister oral calcium supplements of 500 mg and a multiple vitamin
containing 400 international units of vitamin D
daily.
Administer through a separate vented infusion line and do not allow to
come in contact with any calcium or divalent cation-
containing solutions. (2.3)
DOSAGE FORMS AND STRENGTHS
4 mg per 5 mL single-use vial of concentrate (3)
CONTRAINDICATIONS
Hypersensitivity to any component of Zoledronic Acid Injection (4)
WARNINGS AND PRECAUTIONS
Patients being treated with Zoledronic Acid Injection should not be
treated with